How Spironolactone Affects Male Hormones
Spironolactone significantly disrupts male hormone physiology through multiple mechanisms: it competitively blocks androgen receptors, increases testosterone conversion to estradiol, reduces testicular testosterone production, and displaces testosterone from its binding protein, collectively leading to decreased androgen activity and elevated estrogen levels. 1
Mechanism of Anti-Androgenic Action
Spironolactone functions as a competitive antagonist of both aldosterone and androgen receptors while acting as a weak progesterone receptor agonist. 1 This dual receptor blockade is central to its hormonal side effects in men.
Direct Effects on Testosterone Metabolism
The drug alters testosterone dynamics through three primary pathways:
- Enhances aromatization: Spironolactone increases the conversion of testosterone into estradiol, raising circulating estrogen levels. 1, 2
- Suppresses testicular production: It directly reduces testosterone synthesis in the testes, lowering baseline androgen levels. 1, 3
- Increases testosterone clearance: By displacing testosterone from sex hormone-binding globulin (SHBG), spironolactone accelerates testosterone metabolism and elimination. 1, 4
Temporal Pattern of Hormonal Changes
The endocrine effects follow a predictable sequence:
- Days 2–4: Initial transient rise in plasma testosterone and urinary dehydroepiandrosterone (DHA) occurs. 5
- Days 4–10: Compensatory increase in luteinizing hormone (LH) secretion develops, with normalization of plasma testosterone and DHA excretion. 5
- Beyond 10 days: Sustained increases in androgen catabolism and enhanced conversion to estrogens persist, with progressive elevation of serum estrone and estradiol. 5, 2
Clinical Consequences in Men
Dose-Dependent Gynecomastia Risk
Gynecomastia represents the most common and clinically significant adverse effect, with incidence directly correlated to dose:
- <50 mg/day: Approximately 7% incidence at 6 months 1
- >150 mg/day: Up to 52% incidence at 6 months 1
- Conventional doses (75–150 mg/day): Gradual elevation of serum estrone (statistically significant, P<0.01) and estradiol (trend toward significance) over 12 weeks 2
The pathophysiology involves altered testosterone-to-estradiol ratios resulting from increased metabolic clearance of testosterone (P<0.02) and enhanced peripheral conversion to estradiol (P<0.001). 4
Adrenal Androgen Suppression
In castrated men with prostate cancer, spironolactone significantly decreases plasma levels of:
- Testosterone
- Androstenedione
- Dehydroepiandrosterone
This demonstrates suppression of residual adrenal androgen production. 6
Ultrastructural Testicular Changes
Electron microscopy reveals myelin-like bodies in Leydig cell cytoplasm after 20 days of spironolactone administration, accompanied by decreased plasma testosterone and increased plasma progesterone. 3 These structural changes provide direct evidence of testicular dysfunction at the cellular level.
Management of Anti-Androgenic Side Effects
Dose Reduction Strategy
For men developing gynecomastia on spironolactone, reduce the dose to ≤50 mg/day, which often resolves the issue while maintaining therapeutic efficacy. 7, 8
Alternative Mineralocorticoid Receptor Antagonists
Switch to eplerenone in men experiencing anti-androgenic side effects, as it lacks androgen receptor antagonist activity and does not cause gynecomastia. 7, 8 Eplerenone is the preferred mineralocorticoid receptor antagonist for male patients requiring long-term therapy. 8
If eplerenone proves ineffective or unavailable, amiloride represents a second-line alternative that avoids sex steroid-related adverse effects. 1, 9
Critical Clinical Pitfalls
Prostate Cancer Patients
Avoid spironolactone entirely in men with prostate cancer, particularly those receiving androgen deprivation therapy or abiraterone. 10 Despite its typical anti-androgenic effects, experimental evidence demonstrates that spironolactone can paradoxically act as an androgen receptor agonist in androgen-depleted environments, potentially stimulating prostate cancer proliferation. 10
Pregnancy Risk to Male Fetuses
Spironolactone causes feminization of male fetuses when administered during embryogenesis (gestation days 13–21 in animal models at 200 mg/kg/day). 11 Offspring exposed in utero exhibit dose-dependent decreases in ventral prostate and seminal vesicle weights, with endocrine dysfunction persisting into adulthood. 11 The FDA label explicitly warns to avoid spironolactone in pregnant women due to potential risk to male fetuses. 11
Monitoring Considerations
Unlike hyperkalemia monitoring (which requires frequent checks), hormonal side effects do not require routine laboratory surveillance. 7 Clinical assessment for gynecomastia, breast tenderness, erectile dysfunction, and menstrual irregularities suffices for detecting anti-androgenic effects.